




Background: Population screening for renal cell carcinoma (RCC) using ultrasound has the 
potential to improve survival outcomes; however a cost-effectiveness analysis (CEA) has yet 
to be performed. Due to the lack of existing evidence, we performed structured expert 
elicitation to derive unknown quantities to inform the CEA. 
Objectives: To elicit the cancer stage distribution (proportion of individuals with each stage 
of cancer) for different RCC screening scenarios and the annual transition probabilities for 
undiagnosed disease becoming diagnosed in the NHS. 
Methods: The study design and reporting adhered to the Reporting Guidelines for the Use of 
Expert Judgement in Model-Based Economic Evaluations. The elicitation was conducted 
face-to-face or via telephone between each individual expert and the facilitator, aided by 
online material. For multinomial data, Connor Mosimann and modified Connor Mosimann 
distributions were fitted for each expert and for all experts combined using mathematical 
linear pooling.  
Results : A total of 24 clinical experts were invited, and 71% participated (7 urologists, 6 
oncologists, 4 radiologists). The modified Connor Mosimann distribution provided the best 
fit for the majority of elicited quantities. Greater uncertainty was noted for the elicited 
transition probabilities compared to the elicited stage distributions. 
Conclusion: We performed the first expert elicitation of RCC screening parameters, crucial 
information which will inform the CEA of screening. Additionally, the elicited quantities 
may enable future health economic evaluations assessing the value of diagnostic tools and 







What is already known? 
 A cost-effectiveness of analysis of screening for renal cancer has yet to be performed 
 Structured expert elicitation may inform cost-effectiveness models, as values of 
interest may either be unknown or not directly measurable through research  
 
What does the paper add to existing knowledge? 
 We have performed the first structured expert elicitation of renal cancer screening 
parameters, recruiting a multidisciplinary group of 17 experts (urology, radiology and 
oncology specialists)  
 Our approach, consisting of one-to-one interviews between experts and the facilitator 
which can be delivered online or in person, facilitate data collection, maximise study 
feasibility and limit incomplete data collection 

















Renal cell carcinoma (RCC) is the 7th most common malignancy in the UK [1]. Nearly 30% 
of patients have metastases at presentation, and five year relative survival in these patients is 
only 6% [2]. As such, there is an increasing interest in the role of screening for RCC using 
focused renal ultrasound as a potential method to downstage the disease and save lives [3, 4]. 
One of the perceived barriers to population screening remains the relatively low prevalence 
of the disease in unselected cohorts. It has been estimated that population screening of 
asymptomatic individuals would lead to the identification of between 1 and 3 patients with 
RCC, for every 1000 individuals screened [5]. Therefore, a randomised controlled trial (RCT) 
sufficiently powered to detect an impact on survival would need to recruit hundreds of 
thousands of participants. Additionally, there is currently insufficient evidence regarding the 
benefits of screening for RCC and it is therefore not surprising that such a RCT has yet to be 
undertaken. Small observational studies, recruiting in the order of 10,000 participants, have 
been performed but have collected only limited data [6, 7]. Classically health economic 
evaluations are performed following the publication of clinical studies in order to aid 
decisions regarding the value of implementing new strategies in the health service. Instead, 
we propose that a cost-effectiveness analysis (CEA) and value of information analysis (VOI) 
of screening for RCC may be undertaken using the limited available evidence, prior to a large 
trial being undertaken, aiming to determine the value of investing future funds into a large-
scale trial. Indeed, VOI has been used to examine uncertainty surrounding the optimal 




CEAs often require information which is either not (yet) known or not directly measurable 
through research. There has been a growing body of work regarding expert elicitation to 
derive information for health economic evaluation [9]. In the case of screening for RCC, 
there are a number of unknown quantities, which if determined through expert elicitation 
rather than a large-scale trial, could inform a preliminary cost-effectiveness model and VOI. 
Expert elicitation is defined as the quantitative process of deriving a point estimate of an 
unknown value and, critically, a probability distribution around that value, pooling 
knowledge from one or more experts [10]. The probability distribution is subjective as it 
represents the strength of an expert’s belief that an unknown quantity of interest lies between 
two values.  
 
A number of methods have been described to conduct expert elicitation, gather data and 
aggregate results, each with different advantages and disadvantages. Perhaps the most 
renowned method is the SHeffield ELicitation Framework (SHELF) [9, 11]. This describes 
the process of elicitation through a face-to-face group discussion amongst a small group of 
experts. Recognised limitations include: the time-consuming nature of the exercise, high cost 
and logistical and geographical constraints in assembling national and international experts 
together in one location [10]. A number of alternative methods have therefore been described 
to conduct expert elicitation to bypass these limitations, including independent face-to-face 
assessment of each expert and online assessments [12, 13]. We performed a modification of 
existing expert elicitation methods that facilitate data collection and maximise study 
feasibility. 
 
The aim of this study was to perform a structured expert elicitation exercise to derive 
unknown quantities with which to inform a CEA and VOI of screening for RCC. The results 
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of the elicited quantities are of interest to the reader, as they may enable future health 
economic evaluations in RCC. 
 
Methods 
The design of the study and reporting of results adhered to guidelines described by Iglesias et 
al [10]. Ethics approval was not required [14]. Data were anonymised and no financial 
incentive was provided for the experts. The full expert elicitation exercise, training material 
and evidence dossier are found in the Appendix. 
 
Research rationale and quantities of interest 
 
A decision model was developed, adopting a UK National Health Service (NHS) perspective 
to compare the incremental costs and quality adjusted life years of a hypothetical cohort of 
asymptomatic individuals from the general population, undergoing screening via focused 
renal ultrasound (“one off” screening similar to established abdominal aortic aneurysm 
screening) compared to the standard of care (no screening). The model was populated with 
data identified from a review of the literature. We identified a number of parameters for 
which no data were available, for which we sought expert opinion. The focus of this 
manuscript is on the expert elicitation process and results. The decision-model based 
economic analysis will be reported elsewhere. 
 
We elicited the cancer stage distribution (i.e. the proportion of individuals in each stage) for 
individuals with undiagnosed RCC, individuals with RCC who did not attend screening and 
individuals with RCC who were false negatives at screening. The former encompasses all 
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patients who have RCC but are still undiagnosed in the current NHS (in the absence of 
screening). These individuals are asymptomatic and there is a potential for diagnosis if 
screening were implemented with a perfect test (i.e. no false negatives). Data regarding 
individuals with RCC who are screening non-attenders is unknown and by definition cannot 
be measured even in the context of a prospective trial as these individuals do not attend. Data 
regarding the stage distribution of false negatives at screening is sparse. A previously 
performed systematic review and meta-analysis identified seven studies that delivered 
ultrasound for the identification of RCC in a screening paradigm [5]. Only two studies 
reported false negative rates. In the study by Filipas et al., in order to identify false negatives 
at initial screening ultrasound, participants were re-invited to attend for a second ultrasound 
one year later, in addition to monitoring cancer registry data [6]. In the study by Mizuma et 
al., false negatives were only identified by monitoring registry data rather than repeat 
imaging [15]. In these two studies combined, despite screening 25,983 individuals, only three 
false negative cases were identified. This may either represent the high sensitivity of 
ultrasound or inherent weakness in registry data. Of the three cases, two were stage I (T1a), 
while the third patient had a RCC 2cm in size but had concomitant metastases and therefore 
was stage IV. These data were presented to the clinical experts and it was felt not to represent 
the true stage distribution of false negative disease; the small sample size meant that the 
proportion of false negatives with stage IV RCC (33%) was over-estimated by the current 
data. As such, the decision was made to include this parameter in the expert elicitation. 
Furthermore, we elicited expert opinion regarding the probability of undiagnosed RCC 
becoming diagnosed in the NHS in the absence of screening (annual transition probability), 






1. Determine the stage distribution of: 
a. Individuals with undiagnosed RCC in the current NHS (in the absence of 
screening) 
b. Individuals with RCC who do not attend screening 
c. Individuals with RCC who are false negatives at screening 
 
2. Determine probability of undiagnosed RCC becoming diagnosed (annual transition 
probability) in the current NHS, in the absence of screening 
a. By RCC stage 
b. Overall (all stages combined) 
 
Expert selection and inclusion 
Relevant experts in urology, radiology and oncology were identified by the authors based on 
their expertise in the diagnosis and management of RCC. Participants were selected from a 
variety of centres across the UK, including both academic centres and district general 
hospitals, to capture nationally representative data. A mixture of individuals with both 
academic and clinical expertise were invited to participate. Exclusion criteria consisted of a 
known conflict of interest or known unavailability.  
 
Question framing and piloting 
The expert elicitation exercise was created using Microsoft Excel (Company: Microsoft 
Redmond, Washington, USA). This contained six questions relevant to RCC. The final two 
questions asked participants to score their overall confidence in the answers provided and to 
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score how accurately the data provided represented their beliefs (face validity) on a six-point 
Likert scale, as previously described [12]. The questions were framed in a specific order (not 
randomised) to allow the scenarios to build on each other. At the end, participants were asked 
to review their answers for internal consistency, with both the original and revised answers 
being recorded. The parameter of interest was the stage distribution of patients with RCC, 
multinomial data which may be expressed as a proportion, with questions framed as: 
“Imagine 100 individuals with RCC... how many individuals will be in each stage?” [12]. To 
elicit the annual transition probability of diagnosis, experts were asked: “Imagine 100 
individuals with undiagnosed RCC. In the absence of screening, after one year, how many of 
these will have been diagnosed?” Utilising a sample size of 100 (rather than any larger 
number) minimises spurious precision by limiting proportions to two significant figures [12].  
The quantile approach to elicit quantities of interest was chosen. First, participants were 
asked to report 95% credibility intervals (CrI) for each stage, followed by median estimates. 
Participants were required to generate median estimates for each stage that would sum to a 
total of 100. No constraints were placed on the 95% CrI. 
 
The elicitation process was piloted on three individuals. Several different graphical options 
were proposed relating to the stage distribution of RCC (questions 1-4) and the one voted 
most “user-friendly” by the pilot group adopted in the final study. The Excel document was 
programmed to automatically update the graphical representation as participants typed in 
their answers, to allow experts to visualise their answers in real time. Furthermore, based on 
the pilot group, the decision was made to feedback elicitation results to study participants in a 





The elicitation process 
Experts were invited to participate via email. An evidence dossier summarising known 
evidence was emailed to participants in advance of the elicitation exercise, and experts were 
encouraged to submit additional information to be shared with other participants. The 
evidence dossier was kept brief to avoid expert fatigue, however a full bibliography was 
provided (Appendix). 
The elicitation exercise was conducted either face-to-face or via telephone between each 
individual expert and the facilitator (SHR), with the aid of online material. Experts received a 
copy of the training material and the Microsoft Excel elicitation exercise via email. The 
facilitator delivered one-on-one training regarding the elicitation process to each expert, using 
a power point presentation and material adapted from previous elicitation training materials 
and exercises [9, 12]. Each expert was guided through two “practice questions” unrelated to 
RCC to familiarise them with the process. The experts’ performance on the “practice 
questions” was used to assess whether they had understood the elicitation process. None of 
the experts required further training or practice questions. Participants were then guided 
through the elicitation process and encouraged to ask questions, whilst completing the 
exercise. The training and elicitation process took approximately two hours. 
 
Feedback 
Mathematical aggregation was performed to pool data from the experts and results were 
emailed to each individual, demonstrating their individual raw data as well as the aggregated 





Individual experts reported 95% CrI and median estimates for a hypothetical cohort of 100 
patients with RCC. These were converted into proportions prior to analysis. Mathematical 
linear pooling was performed, with experts weighted equally. For multinomial data, three 
different distributions were applied (Dirichlet, Connor Mosimann and modified Connor 
Mosimann distributions) using the modcmfitr package in R, as previously described [16]. 
Briefly, the Dirichlet is a generalisation of the binomial distribution, and the Connor-
Mosimann (CM) and modified Connor Mosimann (mCM) are further generalisations 
allowing more flexible distributions and thus in theory providing a better fit to elicited data.  
Fitting the distributions makes use of a directed random search algorithm to find the best 
fitting distributions for each elicited quantity for each expert. These distributions are then 
sampled from many times, and the pooled median and 95% CrI calculated. A distribution is 
then fitted to these pooled quantiles, representing the aggregation of all the experts’ beliefs.  
Results from the Dirichlet, CM and mCM distributions were compared against the elicited 
quantiles graphically (by plotting medians and credibility intervals) and directly by 
comparing the goodness of fit measure (SSD, sum of squared deviation between the modelled 
and the elicited quantiles). For binomial data, beta distributions were applied and results 






A total of 24 experts were invited and 71% participated (17 total: 7 urologists, 6 oncologists, 
4 radiologists; Figure 1). Participating experts were based at a variety of institutions in 
England and Scotland, including major University teaching hospitals and district general 
hospitals.  
 
For multinomial data, the Dirichlet, CM and mCM distributions were fitted as planned in the 
prespecified analysis. The Dirichlet distribution provided a very poor fit, therefore results are 
not shown (available from corresponding author). The CM distribution provided the closest 
fit for the elicited cancer stage distribution of undiagnosed RCC in the current NHS, and the 
mCM distribution provided the best fit for the remaining two elicited quantities (Table S1). 
The parameters of the distributions that provided the best fit are shown in table 1 (parameters 
of alternative distributions are in Supplemental Tables S2-S4). The modelled median and 
95% CrI are shown in figures 2-4. 
 
Figure 2 demonstrates the stage distribution of undiagnosed RCC in the current NHS (in the 
absence of screening). The pooled data suggested that the majority of patients would be in 
stage I T1a and stage I T1b. Figure 3 demonstrates the stage distribution of individuals with 
RCC in screening non-attenders. The elicited data suggested that the stage distribution in 
screening non-attenders is slightly shifted towards more advanced disease compared to 
overall undiagnosed RCC in the current NHS, with a marginally smaller proportion in stage I 
T1a and T1b, marginally larger proportion in stages II and III and equal proportions in stage 
IV. Figure 4 demonstrates the stage distribution of individuals with RCC who are false 
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negatives at screening, based on data pooled from all the experts. The median estimate for 
stage I T1a RCC is over 75%, with a median estimate of <10% for stage IV. 
 
For the binomial data, beta distributions were fitted (Table S5). Figure 5 demonstrates the 
probability of undiagnosed renal cancer becoming diagnosis in the current NHS (annual 
transition probability), by RCC stage. Data are demonstrated for radiologists, oncologists and 
urologists analysed separately (Figure 5A-5C). Pooled estimates for all experts combined are 
shown in supplemental figure S1. 
 
Generally, there was more uncertainty (i.e. wider credibility intervals) noted for the elicited 
transition probabilities compared to the elicited stage distributions in figures 2-4. 
For all experts, the greatest uncertainty was noted for stage III and IV disease (Figure 5). 
Urologists consistently estimated a higher probability of localised disease (Stages T1a, T1b 
and stage II) becoming diagnosed compared to the other expert groups, while radiologists 
estimated the probability of stage IV disease becoming diagnosed higher than the other expert 
groups (Figure 5A-C). 
 
Two experts submitted additional information for the evidence dossier. Experts were emailed 
the results obtained by pooling estimates from all study participants, presented in a graphical 
format. None of the experts wished to make modifications to the data. 
 
On a six-point Likert scale, where 1 is not confident and 6 is very confident, the mean and 
median overall confidence scores were 3.8 and 4 respectively (range 2-5). The mean and 





In summary, we elicited expert opinion regarding the stage distribution of individuals with 
RCC in a number of scenarios and the annual transition probability from undiagnosed to 
diagnosed RCC in the absence of screening. Due to the nature of the condition of interest, i.e. 
undiagnosed disease and/or screening non-attenders, this information cannot be estimated by 
a clinical trial or prospective cohort study. Therefore, quantifying these data through expert 




We report pooled estimates from seventeen RCC experts from across the UK, regarding the 
stage distribution (i.e. the proportion of individuals in each stage) for individuals with 
undiagnosed RCC in the absence of screening and individuals with RCC who did not attend 
screening. The experts felt that the stage distribution in screening non-attenders would be 
slightly shifted towards more advanced disease compared to screening attenders (2% stage IV 
RCC in attenders vs 8% in non-attenders) [17]. The clinical relevance of this remains to be 
investigated. Research in other disease areas suggests that screening non-attenders have 
significantly more risk factors for disease and are more often from lower socioeconomic 
backgrounds than screening attenders [18]. There is a growing interest in targeted screening 
of high-risk individuals and indeed a recent pilot study of community based lung cancer 
screening demonstrates that high pick-up rates can be achieved by targeting individuals in 
high-risk and deprived areas by maximising convenience of screening (such as minimizing 




One of the elicited parameters in this study was the stage distribution of individuals with 
RCC who are false negatives at screening. Indeed, ultrasound enables the detection of only 
67-82% of tumours 2-3cm in size, therefore there is a potential for false negatives in small 
masses [4, 20-22]. Two studies in the literature have reported false negative rates of screening 
for RCC to date. Due to the small sample size (n=3), these studies over-estimated the 
proportion of false negatives with stage IV RCC (33%) [6, 15]. The experts felt that the 
median estimate for stage I T1a RCC would be over 75%, with a median estimate of <10% 
for stage IV. This reflects the experts’ knowledge of the accuracy of ultrasound and the 
known evidence. This information will allow a more plausible cost-effectiveness model in the 
context of the limited available data in the literature. 
 
We also report the probability of undiagnosed RCC becoming diagnosed in the NHS, by 
stage (annual transition probability). Urologists consistently estimated a higher probability of 
localised disease (Stages T1a, T1b and stage II) becoming diagnosed compared to the other 
expert groups. This may reflect urologists’ clinical exposure and experience investigating and 
managing localised disease. Furthermore, radiologists estimated the probability of stage IV 
disease becoming diagnosed higher than the other expert groups, potentially reflecting their 
imaging expertise. This highlights the importance of including experts from different 
backgrounds. When elicited parameters vary between expert groups, it may be useful to 
perform a sensitivity analysis in the CEA to evaluate the impact of heterogeneity of results on 







Strengths and Limitations 
We adopted a modification of existing expert elicitation methods, an approach that has 
several strengths and limitations that should be considered when interpreting the data 
obtained [13]. One-on-one interaction between the expert and facilitator, delivered online or 
in person, was selected to maximise feasibility and practicality. This allowed a larger number 
of experts to be recruited than conventional group methods, bypassing any inconveniences 
relating to individual participants’ time schedules and geographical constraints [23]. Indeed, 
SHELF methods recommend between six and ten experts, whereas we were able to recruit 
seventeen. The process also allows individual experts to remain anonymous and avoids 
“group thinking” which may occur in the presence of assertive or dominant experts within a 
group exercise [24], although an experienced group facilitator may be able to skilfully avoid 
this. In addition, one-on-one interaction with the facilitator ensures that the expert fully 
understands the elicitation process, engages with the exercise and completes all the 
components. This avoids incomplete submissions or the exercise being interrupted, which is 
often noted in purely online group methods previously described [12]. However, a potential 
limitation is that experts were asked to feedback on pooled data via email. None of our 
experts wished to change their results. It is unclear if this is due to lack of engagement or 
whether the pooled data accurately represented their beliefs. Two experts commented on the 
evidence dossier and one added additional evidence for circulation to the group, suggesting a 
degree of engagement. 
 
A number of different methods to elicit the quantity of interest have been described. In the 
histogram and chip-and-bin approaches, experts are asked to place crosses or chips 
respectively, in equally sized bins at fixed intervals, representing the strength of their belief 
regarding a specific quantity of interest [9]. This allows the expert to visualise graphically 
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their probability density function (PDF) [23]. For example, this method has been used in a 
Health Technology Assessment of Screening for Oral Cancer to estimate the proportion of 
individuals with undiagnosed oral cancer whose disease will progress to a higher stage within 
one year [25]. A reported limitation of this method is that experts tend to focus on the shape 
of the PDF rather than the probabilities [9]. Another commonly used method is the bisection 
or quantile approach, in which experts are asked to report median estimates for a particular 
quantity of interest, in addition to other quantiles, usually tertiles or quartiles. This allows the 
expert to divide their plausible range into equiprobable sections. However, clinical experts 
who do not have a statistical background often experience difficulty placing tertiles and 
quartiles, underestimating the proximity of these values to the median [9]. We utilized the 
quantile approach to elicit parameters of interest. Importantly, participants were asked to 
report 95% credibility intervals first, followed by median estimates, as this has been 
suggested to minimize heuristics such as anchoring and overconfidence [26]. We 
acknowledge that using the median and 95% credibility intervals reduces the available data 
and may make it more difficult to fit a parametric distribution, however this method is easier 
to understand for clinical experts through familiarity with 95% confidence intervals and 
therefore increases internal consistency [27]. In addition, clinicians report higher face validity 
with the quantile approach [28]. Indeed, our participants reported a mean face validity score 
of 5.25 out of 6, consolidating these findings. There is a paucity of studies directly comparing 
the impact of different elicitation methodology on outcomes and further comparative research 
in this field is paramount [29]. 
 
Generally, more uncertainty (i.e. wider credibility intervals) was noted for the elicited 
transition probabilities compared to the elicited stage distributions. This may reflect the 
clinical experts’ genuine uncertainty as to appropriate values.  However, this could also 
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reflect relatively low familiarity with the concept of transition probabilities and difficulty 
estimating rate of change, which may impact interpretation of results. To overcome this 
known challenge, particular attention was paid to training experts and questions regarding 
transition probabilities were framed as frequencies rather than probabilities, as previously 
described [12, 29]. It is important to ensure, through adequate training, that experts are 
expressing uncertainty rather than heterogeneity. In addition, the training session alerted the 
experts to the concept of cognitive biases such as anchoring and overconfidence, aiming to 
reduce these. There is no established method to evaluate whether experts have achieved 
sufficient normative skills, therefore studies often request experts to rate their overall 
confidence in the expert elicitation process [12]. The mean confidence scores reported by our 
experts were similar to those previously reported in other expert elicitation exercises, 
suggesting experts were satisfied with the training received and the answers provided [12].  
We performed mathematical linear pooling with equal weighting for all experts as there is 
uncertainty regarding the identification of suitable seed questions which are clinically 
meaningful and which accurately represent the experts’ knowledge [29]. Furthermore, 
introducing seed questions may increase the overall number of questions in the elicitation and 
contribute to expert fatigue [13, 23]. We acknowledge that the absence of seed questions 
precluded an analysis of expert calibration. Further research into the quantity and quality of 











We report pooled data from seventeen RCC experts from across the UK, across three 
different clinical specialties. The relatively large sample size, compared to other expert 
elicitation exercises of this nature, increases the reliability and validity of our results. One-on-
one interaction between each expert and the facilitator aided data collection, maximised study 
feasibility and limited incomplete data submissions. We have performed the first expert 
elicitation of RCC screening parameters, crucial information which will inform a CEA of 
screening. Additionally, the elicited quantities may enable future CEAs assessing the value of 



















Figure 1: Study participants and host institutions 
 
Figure 2: Stage distribution of undiagnosed renal cancer in the current NHS (pooled expert 
beliefs), including median (dot) and 95% credibility intervals (lines) 
 
Figure 3: Stage distribution of individuals with renal cancer who do not attend screening 
(pooled expert beliefs), including median (dot) and 95% credibility intervals (lines) 
 
Figure 4: Stage distribution of individuals with renal cancer who are false negatives at 
screening (pooled expert beliefs), including median (dot) and 95% credibility intervals (lines) 
 
Figure 5: Probability of undiagnosed renal cancer becoming diagnosed in the current NHS 
(annual transition probability), by renal cancer stage. Median (dot) and 95% credibility 
intervals (lines) are shown. Data is demonstrated for radiologists (A), oncologists (B) and 
urologists (C) analysed separately. Data demonstrating values for all experts combined is 




Table 1: Table 1 demonstrates the pooled data from all 17 experts regarding the stage distribution of RCC in three scenarios: undiagnosed 
individuals in the current NHS, screening non-attenders and screening false negatives. Parameters are shown for the distribution which provided 
the best fit, along with modelled medians (Med) and 95% lower and upper credibility intervals (LCrI and UCrI).* 
 
 
*Note: Modelled medians do not sum to 1, however means will (data not shown). Ordering of Zed parameters is critical to ensure correct 







 Stage distribution of undiagnosed RCC in the NHS  Stage distribution of screening non-attenders Stage distribution of false negatives at screening 
 Connor Mosimann distribution  Modified Connor Mosimann distribution Modified Connor Mosimann distribution 
Stage Zed LCrI Med UCrI a b  Zed LCrI Med UCrI a b L U  Zed LCrI Med UCrI a b L U 
I T1a 
1 
0.14 0.39 0.7 4.228455 6.262833  1 
0.11 0.31 0.54 3.929694 5.093263 0.001468 0.721504 
 
1 





0.04 0.25 0.58 2.077874 2.643674  2 
0.11 0.29 0.49 4.030906 2.812999 0.004625 0.721208 
 
2 





0.01 0.08 0.32 1.140113 1.223572  5 
0.04 0.13 0.31 - - - - 
 
4 





0.02 0.10 0.28 5.321397 9.908572  3 
0.06 0.15 0.31 6.908978 9.938337 0.002224 0.996406 
 
5 





0.01 0.09 0.33 - -  4 
0.01 0.08 0.23 1.815232 2.702502 0.003505 0.957281 
 
3 
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